Alcohol on GLP-1 Medications: What Actually Happens in Your Body

What the labels say about alcohol

Wegovy's contraindication list is short: a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and a prior serious hypersensitivity reaction to semaglutide or an excipient. Alcohol is not on it [1]. The label's drug interactions section covers insulin, insulin secretagogues such as sulfonylureas, and oral medicines whose absorption may shift when gastric emptying slows; alcohol is not named there either [1].

Foundayo (orforglipron) has a different interactions list: strong CYP3A4 inhibitors and inducers, simvastatin, insulin or sulfonylureas, and oral hormonal contraceptives. Alcohol is not listed [2].

What both labels do describe at length is the gut. In Wegovy's weight-management trials at 2.4 mg weekly for up to 68 weeks, nausea occurred in 44% of patients versus 16% on placebo, diarrhea in 30% versus 16%, vomiting in 24% versus 6%, and constipation in 24% versus 11% [1]. At the 17.2 mg Foundayo dose across two pooled 72-week trials, nausea ran 35% versus 10%, vomiting 24% versus 4%, diarrhea 25% versus 11%, and constipation 24% versus 9% [2]. Rates from separate trials are not directly comparable to each other [1][2].

Both labels also warn about acute kidney injury from volume depletion. The Foundayo label notes that most reported cases followed gastrointestinal reactions such as nausea, vomiting or diarrhea that led to dehydration, and says to monitor renal function in patients reporting reactions that could cause volume loss [2]. The Wegovy label carries the same warning [1].

Does alcohol hit harder on a GLP-1 drug?

The semaglutide, tirzepatide and orforglipron labels all state that the drug delays gastric emptying and that this can affect the absorption of oral medicines [1][3][2]. Alcohol is absorbed from the gut and mostly oxidized in the liver, and how high blood alcohol climbs depends on how fast it is absorbed, how much is cleared on the first pass through the liver, and how quickly the rest is eliminated [6].

We found no study of whether a slower-emptying stomach changes the height or timing of the blood alcohol curve in someone taking semaglutide, tirzepatide or orforglipron, and the labels do not say how drinking changes the dehydration and kidney risks they describe [1][2].

Alcohol's effect on urine output has been measured, though not in people taking a GLP-1 drug. Twelve men drank 1 liter of beer containing 4% ethanol after being rehydrated, and produced 1,279 mL of urine over four hours against 1,121 mL when the same beer was alcohol-free (P<0.001). When the same men started about 2% of body mass down in fluid, the difference between the alcoholic and non-alcoholic beer was not significant (261 versus 174 mL, P=0.057) [7]. That is what was measured: urine volume after a liter of weak beer.

Blood sugar: what the labels warn about

The Wegovy label raises hypoglycemia as a risk when the drug is combined with insulin or an insulin secretagogue, and says a lower dose of that insulin or secretagogue may be necessary [1]. In a Wegovy trial in adults with type 2 diabetes and a BMI of at least 27, plasma glucose below 54 mg/dL was reported in 6% of Wegovy patients versus 2% of placebo patients, none of them on insulin [1].

The Foundayo label gives its own numbers from its type 2 diabetes trial: glucose below 54 mg/dL in 2% of orforglipron-treated patients versus 0.2% on placebo, and 7% among those also taking a sulfonylurea versus 0.5% among those who were not [2]. It adds that hypoglycemia has also been reported with GLP-1 receptor agonists in adults without type 2 diabetes [2].

In both labels the named partners are insulin and insulin secretagogues, and alcohol is not mentioned in the hypoglycemia warning [1][2].

Pancreatitis

Both labels carry an acute pancreatitis warning. The Wegovy label states that acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed with GLP-1 receptor agonists including Wegovy; that patients should be watched for persistent or severe abdominal pain, sometimes radiating to the back, which may or may not come with nausea or vomiting; and that Wegovy should be discontinued and appropriate management started if pancreatitis is suspected [1]. The Foundayo label uses the same structure [2].

In the pooled Foundayo trials there were 6 adjudicated acute pancreatitis events in 6 orforglipron-treated patients (0.14 per 100 years of exposure) versus 2 events in 1 placebo-treated patient (0.04 per 100 years of exposure) [2]. Neither warning puts a number on any added risk from drinking [1][2].

Does semaglutide make people drink less?

This is the direction with actual trial data, and results differ by drug.

Preclinical studies show GLP-1 receptor agonists decreasing alcohol intake, the motivation to consume alcohol and relapse drinking, potentially by lowering alcohol-induced reward; the central mechanisms are not fully defined [8]. A separate review of studies in rodents and non-human primates suggests the effect is mediated centrally, at least partly through dopamine signalling, with the precise mechanisms still to be uncovered [9].

In people, exenatide was tested first. In a 26-week double-blind trial, 127 treatment-seeking adults with alcohol use disorder received exenatide 2 mg weekly or placebo, both with cognitive behavioral therapy. Exenatide did not significantly reduce the primary outcome, heavy drinking days, but it did dampen fMRI reactivity to alcohol cues in the ventral striatum and septal area, and exploratory analyses found significant reductions in heavy drinking days and total alcohol intake in the subgroup with a BMI above 30 [5].

Semaglutide produced a positive result in a 2026 Lancet trial: 108 treatment-seeking adults with moderate to severe alcohol use disorder and comorbid obesity, 54 per group, took semaglutide 2.4 mg weekly or placebo for 26 weeks alongside cognitive behavioral therapy. Heavy drinking days fell 41.1 percentage points from baseline with semaglutide versus 26.4 with placebo, an estimated difference of 13.7 points (95% CI -22.0 to -5.4; p=0.0015). Adverse events were transient and mostly mild to moderate gastrointestinal effects, more frequent with semaglutide [4].

A 2025 systematic review of three randomized trials (48 to 151 participants each) summarized it this way: semaglutide reduced alcohol use, dulaglutide lowered alcohol intake in current drinkers, and exenatide had no significant effect on heavy drinking days, with larger trials needed [10].

None of this makes alcohol use disorder an approved use. Wegovy is approved for weight reduction, cardiovascular risk reduction and MASH, Foundayo for weight reduction, and the diabetes products for type 2 diabetes and related outcomes [1][2][11].